Brexpiprazole for schizophrenia and as adjunct for major depressive disorder: a systematic review of the efficacy and safety profile for this newly approved antipsychotic - what is the number needed to treat, number needed to harm and likelihood to be hel

Efficacy and Safety of Brexpiprazole for the Treatment of Acute Schizophrenia: A 6-Week Randomized, Double-Blind, Placebo-Controlled Trial

(2015) Christoph U. Correll et al.   AMERICAN JOURNAL OF PSYCHIATRY

Potentiation of neurite outgrowth by brexpiprazole, a novel serotonin–dopamine activity modulator: A role for serotonin 5-HT1A and 5-HT2A receptors

(2015) Tamaki Ishima et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

Improvement of dizocilpine-induced social recognition deficits in mice by brexpiprazole, a novel serotonin–dopamine activity modulator

(2015) Noriko Yoshimi et al.   EUROPEAN NEUROPSYCHOPHARMACOLOGY

A multicenter, randomized, double-blind, controlled phase 3 trial of fixed-dose brexpiprazole for the treatment of adults with acute schizophrenia

(2015) John M. Kane et al.   SCHIZOPHRENIA RESEARCH

Effects of brexpiprazole, a novel serotonin-dopamine activity modulator, on phencyclidine-induced cognitive deficits in mice: A role for serotonin 5-HT1A receptors

(2014) Noriko Yoshimi et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

A Review of the Pharmacology, Efficacy and Tolerability of Recently Approved and Upcoming Oral Antipsychotics: An Evidence-Based Medicine Approach

(2013) Leslie Citrome   CNS DRUGS

Cariprazine: chemistry, pharmacodynamics, pharmacokinetics, and metabolism, clinical efficacy, safety, and tolerability

(2013) Leslie Citrome   Expert Opinion on Drug Metabolism & Toxicology

New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia

(2013) Leslie Citrome   Expert Review of Neurotherapeutics

When does a difference make a difference? Interpretation of number needed to treat, number needed to harm, and likelihood to be helped or harmed

(2013) L. Citrome et al.   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis

(2013) Stefan Leucht et al.   LANCET

On-label on the table: what the package insert informs us about the tolerability profile of oral atypical antipsychotics, and what it does not

(2011) Leslie Citrome et al.   EXPERT OPINION ON PHARMACOTHERAPY

Iloperidone redux: a dissection of the Drug Approval Package for this newly commercialised second-generation antipsychotic

(2010) L. Citrome   INTERNATIONAL JOURNAL OF CLINICAL PRACTICE

Adjunctive Aripiprazole, Olanzapine, or Quetiapine for Major Depressive Disorder: An Analysis of Number Needed to Treat, Number Needed to Harm, and Likelihood to be Helped or Harmed

(2010) Leslie Citrome   POSTGRADUATE MEDICINE

Oral antipsychotics for the treatment of schizophrenia: heterogeneity in efficacy and tolerability should drive decision-making

(2009) Jan Volavka et al.   EXPERT OPINION ON PHARMACOTHERAPY

Compelling or irrelevant? Using number needed to treat can help decide

(2008) L. Citrome   ACTA PSYCHIATRICA SCANDINAVICA

Antipsychotics for the treatment of schizophrenia: likelihood to be helped or harmed, understanding proximal and distal benefits and risks

(2008) Leslie Citrome et al.   Expert Review of Neurotherapeutics